Navigation Links
WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs
Date:4/30/2010

SALT LAKE CITY, April 30 /PRNewswire-FirstCall/ -- World Heart Corporation (WorldHeart; Nasdaq: WHRT), a developer of mechanical circulatory systems, announced the appointment of Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs. Dr. Woodard will be responsible for clinical affairs and will also guide the development of World Heart's next- generation technologies. Dr. Woodard most recently served as Chief Scientific Officer for Ventracor Limited: an Australian-based public company focused on the development of left ventricular assist devices for late-stage heart failure patients. Prior to that, Dr. Woodard has served in various senior management positions in a number of medical device companies including, Micromedical Industries Limited, CHAD Research Laboratories, Novacor Division of Baxter Healthcare Corporation and Heart Research Institute of San Francisco.

Dr. Woodard's educational accomplishments include a Bachelor in Electrical Engineering, a Master of Science in Biophysics and a Doctor of Philosophy in Biomedical Engineering at the University of South Wales.  Dr. Woodard has been awarded over 14 medical device related patents and he has authored numerous peer-reviewed papers and abstracts.

J. Alex Martin, President and CEO of WorldHeart commented, "We are extremely pleased to have a well recognized and respected leader in the field of Mechanical Circulatory Support join WorldHeart. We look forward to John's contributions to our efforts to serve patients suffering from advanced heart failure."

Jal S. Jassawalla, Executive Vice President and Chief Technology Officer added, "I'm delighted to welcome John back and look forward to having him be part of the WorldHeart team."

Dr. Woodard will relocate to WorldHeart's corporate headquarters in Salt Lake City, Utah with an anticipated start date of May 17, 2010.

About the Levacor VAD and World Heart Corporation

The Levacor VAD is the only fully magnetically levitated, bearingless, implantable centrifugal pump to move into clinical trial.  By using magnetic levitation to fully suspend a spinning rotor, the Levacor VAD's only moving part, the pump is designed to eliminate wear and to provide unobstructed clearances for blood flow across a wide range of operation.

WorldHeart is a developer of mechanical circulatory support systems based in Salt Lake City, Utah with additional facilities in Oakland, California, USA. WorldHeart's registered office is in Delaware, USA.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to WorldHeart's reliance on key executive officers, its BTT clinical study of the Levacor VAD, strategic direction, increase in shareholder value, access to investment capital, its clinical development programs and the product pipeline, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: risks involved in the clinical trials of the Levacor VAD; reliance on key executive officers; WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K  for the year ended December 31, 2009.

www.worldheart.com


'/>"/>
SOURCE World Heart Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
2. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
3. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
4. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
5. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
6. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
7. NASDAQ Stock Market Confirms WorldHearts Compliance With NASDAQ Listing Rule 5605
8. WorldHeart Reports 2009 Financial Results
9. Quark Pharmaceuticals Appoints New Chief Medical Officer
10. West Pharmaceutical Services, Inc. Appoints New Director
11. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... development of a once-daily, oral therapy for the treatment ... Officer, Dr. Maya Halpern , has notified the Company ... Officer and from its Board of Directors effective as ... age. Allen Baharaff . Mr. Baharaff continued, ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... in the U.S. and Europe , announced ... laser at the upcoming 151 st Midwinter Meeting of ... #4815. The ST PRO is a full featured hard and ... the award winning, industry leading Lightwalker ATS. At an introductory price ... attractive to many dentists hesitating to incorporate lasers into their ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... and ergoFET force gauges used in physical therapy, occupational therapy and sports medicine ... for resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
Breaking Medicine News(10 mins):